PMID- 25340263
OWN - NLM
STAT- MEDLINE
DCOM- 20160222
LR  - 20171116
IS  - 1473-0804 (Electronic)
IS  - 1369-7137 (Linking)
VI  - 18
IP  - 3
DP  - 2015 Jun
TI  - Bazedoxifene blocks AGEs-RAGE-induced superoxide generation and MCP-1 level in 
      endothelial cells.
PG  - 426-30
LID - 10.3109/13697137.2014.958073 [doi]
AB  - Advanced glycation endproducts (AGEs) and their receptor (RAGE) play a role in 
      vascular complications in diabetes. We have previously shown that 17beta-estradiol 
      at 10 nmol/l, a nearly identical plasma concentration to that during 
      mid-pregnancy, up-regulates RAGE expression in endothelial cells. The finding 
      might suggest the involvement of 17beta-estradiol in the deterioration of vascular 
      complications in diabetes during pregnancy. However, the effects of the selective 
      estrogen receptor modulator, bazedoxifene, on oxidative and inflammatory 
      reactions in AGEs-exposed endothelial cells remain unknown. In this study, we 
      addressed the issue. Ten nmol/l 17beta-estradiol increased RAGE and monocyte 
      chemoattractant protein-1 (MCP-1) gene and protein expression in human umbilical 
      vein endothelial cells (HUVECs), both of which were blocked by 10 nmol/l 
      bazedoxifene. Bazedoxifene at 10 nmol/l also significantly inhibited the 
      AGEs-induced superoxide generation, RAGE and MCP-1 gene and protein expression in 
      HUVECs. The present study suggests that blockade of the AGEs-RAGE axis by 
      bazedoxifene might be a novel therapeutic target for preventing vascular damage 
      in diabetes, especially in postmenopausal women.
FAU - Ishibashi, Y
AU  - Ishibashi Y
AD  - Department of Pathophysiology and Therapeutics of Diabetic Vascular 
      Complications.
FAU - Matsui, T
AU  - Matsui T
FAU - Ueda, S
AU  - Ueda S
FAU - Fukami, K
AU  - Fukami K
FAU - Okuda, S
AU  - Okuda S
FAU - Ohta, H
AU  - Ohta H
FAU - Yamagishi, S
AU  - Yamagishi S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141023
PL  - England
TA  - Climacteric
JT  - Climacteric : the journal of the International Menopause Society
JID - 9810959
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Indoles)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Selective Estrogen Receptor Modulators)
RN  - 11062-77-4 (Superoxides)
RN  - Q16TT9C5BK (bazedoxifene)
SB  - IM
MH  - Cells, Cultured
MH  - Chemokine CCL2/genetics/*metabolism
MH  - Human Umbilical Vein Endothelial Cells/*metabolism
MH  - Humans
MH  - Indoles/*administration & dosage
MH  - Oxidative Stress/drug effects
MH  - Receptor for Advanced Glycation End Products/genetics/*metabolism
MH  - Selective Estrogen Receptor Modulators/*administration & dosage
MH  - Superoxides/*chemistry
OTO - NOTNLM
OT  - AGEs
OT  - BAZEDOXIFENE
OT  - CARDIOVASCULAR DISEASE
OT  - OXIDATIVE STRESS
OT  - RAGE
OT  - SERM
EDAT- 2014/10/24 06:00
MHDA- 2016/02/24 06:00
CRDT- 2014/10/24 06:00
PHST- 2014/10/24 06:00 [entrez]
PHST- 2014/10/24 06:00 [pubmed]
PHST- 2016/02/24 06:00 [medline]
AID - 10.3109/13697137.2014.958073 [doi]
PST - ppublish
SO  - Climacteric. 2015 Jun;18(3):426-30. doi: 10.3109/13697137.2014.958073. Epub 2014 
      Oct 23.